KC-WISE: what clinicians are saying
KN026 in HER2-positive advanced gastric cancer after failed first-line therapy · NCT05427383 ↗ · Phase 2/Phase 3 · Shanghai JMT-Bio Inc.
A medical oncologist reads KC-WISE as a signal for changing care, citing benefit from continued HER2 targeting; another considers the interim overall-survival data too immature for that judgment. A physician leans toward T-DXd for now, while considering later anbenitamab for patients with lung disease. Differences among secondary accounts remain unresolved without an original results publication in the sources reviewed. The sources place interim results at ESMO 2025 and the updated OS analysis at ESMO 2026.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 77 verified statements
This edition $750, with MCP access for your AI agent. Get this report
8 findings, and what sits behind each
01. KC-WISE: where speakers split on readiness to change practice
3 of the report's 7 cited clinicians · 11 statements from 5 speakers in 7 sources · 9 passages
Limitations recorded: 2.
Draws on: Design and conduct, Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC, Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC, Population and setting, The comparison, Secondary endpoints, Safety and tolerability.
02. KC-WISE results: how speakers weigh the chemotherapy-only comparator
2 of the report's 7 cited clinicians · 5 statements from 3 speakers in 3 sources · 3 passages
Limitations recorded: 2.
Draws on: The comparison, Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC, Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC, Population and setting, Design and conduct, Safety and tolerability.
03. KN026 beyond T-DXd: what speakers say
3 of the report's 7 cited clinicians · 8 statements from 4 speakers in 5 sources · 5 passages
Limitations recorded: 2.
Draws on: The comparison, Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC, Population and setting, Safety and tolerability, Design and conduct.
04. KC-WISE safety: where speakers split on added toxicity versus chemotherapy alone
6 of the report's 7 cited clinicians · 20 statements from 11 speakers in 17 sources, 2 of them podcasts or videos · 20 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Secondary endpoints, Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC, Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC, The comparison, Population and setting, Design and conduct.
05. KC-WISE curves: why a speaker looks beyond medians for long-term outcomes
No named clinician · accounts and unnamed speakers · 8 statements from 1 speaker in 1 source, a podcast or video · 11 passages
Limitations recorded: 2.
Draws on: Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC, Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC, Secondary endpoints, Safety and tolerability.
06. Dual HER2 targeting: what most speakers highlight, while some use ADC terms
4 of the report's 7 cited clinicians · 31 statements from 10 speakers in 17 sources, 2 of them podcasts or videos · 22 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC, Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC, Secondary endpoints, The comparison, Safety and tolerability, Population and setting, Design and conduct.
Beyond the trial population
07. Chemotherapy with KN026: a speaker thinks it is probably unnecessary in routine care
1 of the report's 7 cited clinicians · 5 statements from 2 speakers in 3 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 3.
08. KN026 at lower HER2 expression: why a speaker expects activity
No named clinician · accounts and unnamed speakers · 4 statements from 1 speaker in 1 source, a podcast or video · 8 passages
Limitations recorded: 4.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 8
3 of the report's 7 cited clinicians
KC-WISE: where speakers split on readiness to change practice
11 statements from 5 speakers in 7 sources
5 of the 5 named speakers in this finding take a side on this question: 1 on one side, 4 on the other
- 11
- statements
- 9
- passages
- 7
- sources
- 5
- speakers
What the statements areViews 10Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 14Giving context 0Recorded with the findingLimitations: 2
7 posts and articles
Draws on: Design and conduct, Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC, Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC, Population and setting, The comparison, Secondary endpoints, Safety and tolerability.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 8 findings and 7 of the 77 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (12)
ADC, antibody–drug conjugate; ESMO, European Society for Medical Oncology; GEJ, gastroesophageal junction; HCP, healthcare professional; HER2, human epidermal growth factor receptor 2; IRC, independent review committee; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; T-DXd, trastuzumab deruxtecan.
The full KC-WISE report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians need from mature overall-survival follow-up and global validation to decide whether KC-WISE’s anbenitamab plus chemotherapy should change practice after trastuzumab failure in HER2-positive gastric/GEJ cancer?
From finding F1 (11 statements from 5 speakers in 7 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 43commentary sources screened
- 25sources cited by verified statements
- 13named in screened sources
- 13speakers cited in the report
- 12cited speakers with a verified identity
7 cited clinicians, speakers with a confirmed clinical role, of them 7 physicians. By role and specialty:
- 5 physician, Medical oncology
- 1 physician, specialty not confirmed
- 1 physician, Gastroenterology
Also in the sources: 2 organizational or shared accounts, not counted as people.
- 77verified statements, each linked to its source
- 26of them from speakers with a confirmed clinical role
- 8findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 77 | Paid |
| Who said each statement: the cited speakers | 13 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 12 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 25 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
13 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC | 24 | 19 |
| Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC | 24 | 20 |
| Secondary endpoints | 19 | 16 |
| Population and setting | 9 | 7 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 11 | 8 |
| Safety and tolerability | 17 | 16 |
| Design and conduct | 9 | 6 |
| Clinical readiness, global validation and HER2 reassessment | 11 | 7 |
| Post-trastuzumab alternatives, access and HER2-treatment sequencing | 10 | 7 |
| Dual-epitope rationale and drug-class terminology | 20 | 9 |
| Survival-curve interpretation and communication | 8 | 1 |
| Chemotherapy-free extrapolation outside the tested regimen | 5 | 3 |
| Lower-HER2 predictions, testing labels and patient support | 4 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
77 verified statements from 25 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 33 statements · 43% | ||||
| YouTube | 33 | 2 | 2 | |
| Posts · 44 statements · 57% | ||||
| X threads | 43 | 22 | 40 | |
| LinkedIn posts | 1 | 1 | 1 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 18 / quarter
- Screened window
- Sep 27, 2025 → Nov 1, 2026
- Cited window
- Oct 16, 2025 → Oct 23, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.
- Registry
- NCT05427383
- Study IDs
- KN026-001
- Sponsor
- Shanghai JMT-Bio Inc.
- Design
- Phase 2/Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 286 estimated
- Registered
- 2022-06-22
- Start
- 2022-04-07 actual
- Primary completion
- 2025-11 estimated
- Primary endpoints
- Progression Free Survival (PFS) according to RECIST 1.1 by IRC
- Overall Survival (OS) according to RECIST 1.1 by IRC
- Interventions
- 4 registered
More on: Gastric cancer
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- Not yet captured in this edition: a view on the survival-benefit versus toxicity trade-off of antibody plus chemotherapy after first-line treatment.
- 1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition.
- 25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
Show all 12 known gaps +Fewer −
- Further source limits: 44 sources about other trials or topics are not included.
- This report characterizes the sources reviewed for this edition, not all HCP discussion or the prevalence of any opinion. Repeated posts and reposts are not independent endorsements.
- Potentially relevant discussion may be missing where the trial or KN026 is not named or is described differently. One X conversation could not be read, and part of a video was not fully assessed.
- No full protocol or original trial results publication is included. Linked article information and secondary summaries cannot independently resolve disagreements about study conduct or results.
- Authors report different response rates, event definitions and analysis populations. These accounts are kept distinct rather than pooled into one results summary.
- Some comments about survival-curve interpretation, stratification and Canadian prescribing have no identifiable speaker. They cannot be assigned to a named speaker or counted as independent agreement.
- Product-specific regulatory information is incomplete. Statements about historical approval, availability or prescribing remain attributed accounts, not independently established regulatory conclusions.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 1 fix (tags)
None of these changed a statement, finding or source.
- Nov 19, 2026 UTCtaxonomy mapping corrected
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. KC-WISE (NCT05427383): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/kc-wise-nct05427383
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "KC-WISE" (NCT05427383), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "kc-wise-nct05427383". If you cannot make requests, read https://www.erudio.com/reports/kc-wise-nct05427383.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05427383", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05427383 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/kc-wise-nct05427383.json
curl https://www.erudio.com/reports/kc-wise-nct05427383.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "kc-wise-nct05427383" })release 036d532bb7b86680e2d49f8c92b082e2e6aca5df96075cc1553e271d3d86cd14
Questions
How much does the KC-WISE report cost?
One edition costs $750 (Focused · 77 verified statements · 26 from 7 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the KC-WISE report cover?
77 statements from 25 sources (2 videos, 23 posts), 26 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the KC-WISE report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "kc-wise-nct05427383" }) previews it and create_order({ "report": "kc-wise-nct05427383", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the KC-WISE report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.